About the DTU
› Home page
Software
› HOMA Calculator
Current Studies
› 4-T
Completed Studies
› ADOPT
Intranet
Search
| UKPDS~Post Trial Monitoring |  |
 |
|
Results |
|
Intensive (sulfonylurea/insulin) versus Conventional (diet) glucose controlThe UKPDS Post-Trial monitoring results showed continuing benefit of earlier improved glucose control, with maintenance of the relative risk reductions reported in 1998 for any diabetes related endpoint (9%, P=0.04) and microvascular disease (24%, P=0.001), despite loss of within trial blood glucose and antihyperglycaemic therapy differences – a legacy effect. In addition, significant relative risk reductions emerged for myocardial infarction (15%, P=0.014) and all-cause mortality (12%, P=0.007). Intensive (metformin) versus Conventional (diet) glucose control in overweight patientsThe UKPDS Post-Trial monitoring results showed continuing benefit of earlier metformin therapy, with maintenance of the relative risk reductions reported in 1998 for any diabetes related endpoint (21%, P=0.013), myocardial infarction (33%, P=0.005) and all-cause mortality (27%, P=0.002), despite loss of within trial blood glucose and antihyperglycaemic therapy differences – a legacy effect. No significant changes were seen during or after the trial with respect to microvascular disease. See: UKPDS 80, N Eng J Med 2008; 359 Holman et al Tight versus Less-tight blood pressure controlThe UKPDS Post-Trial monitoring results showed that the risk reductions reported in 1998 for any diabetes related endpoint and for microvascular disease were not maintained following the loss of within trial blood pressure and antihypertensive therapy differences. No significant changes were seen during or after the trial with respect to myocardial infarction or all-cause mortality. See: UKPDS 81, N Eng J Med 2008; 359 Holman et al |
|
 |
|
|
|
